Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial. (linkinghub.elsevier.com)

Authors: Lan B … Xu B Journal: The Lancet Published: 2026-10-26 DOI: https://doi.org/10.1016/S0140-6736(26)02096-9